ZBIO
Zenas BioPharma, Inc.
Next earnings Aug 10, 2026 · consensus $-1.15 EPS, $19.1M rev
Last earnings +4.0% on 2026-05-13
$25.87
▲ +4.86%$25.87▲ +170.04%
over 1Y
L $9.14EODHDH $43.17
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+4.9%
1W+4.9%
1M+43.0%
3M+42.1%
YTD-25.0%
1Y+170.0%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 14 analysts
Strong Buy
Revenue grew 100.0% YoY; but unprofitable (net margin -3777.4%).
Revenue (FY2025) $10.0M · FY2025
Zenas BioPharma, Inc. shows $10.0M in FY2025 revenue (+100.0% YoY), a -3777.4% net margin, and -156.0% ROE.
Financials · annual, by fiscal year
| Line item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | $50.0M | $5.00M | $10.0M |
| Gross profit | — | — | — |
| Operating income | -$37.1M | -$164M | -$383M |
| Net income | -$37.1M | -$157M | -$378M |
| Diluted EPS | -$24.25 | -$11.89 | -$8.44 |
| Net margin | -74.2% | -3139.8% | -3777.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$1.45B
EV / EBITDA—
EV / Sales145.2
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-25.5%
FCF yield-11.6%
Quality & risk
ROIC (est.)-94.3%
Free cash flow-$172M
Total debt$78.6M
Net cash$32.0M
Altman Z-Score1.13 distress
Piotroski F-Score2/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+37.2%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Officer / director change2026-05-13
- 10-Q Quarterly report2026-05-13
- 8-K Material agreement2026-03-31
- 8-K Earnings results2026-03-16
- DEF 14A Proxy statement2026-03-16
- 10-K Annual report2026-03-16
- 8-K Officer / director change2026-02-13
- 8-K Earnings results2026-01-05
- 8-K Officer / director change2025-12-15
Recent filings
all on EDGAR ↗4Period ending 2026-06-152026-06-17open ↗4Period ending 2026-06-152026-06-17open ↗4Period ending 2026-06-152026-06-17open ↗4Period ending 2026-06-152026-06-17open ↗4Period ending 2026-06-152026-06-17open ↗4Period ending 2026-06-152026-06-17open ↗4Period ending 2026-06-152026-06-17open ↗4Period ending 2026-06-152026-06-17open ↗4Period ending 2026-06-152026-06-17open ↗4Period ending 2026-06-152026-06-17open ↗4Period ending 2026-05-182026-05-18open ↗10-QPeriod ending 2026-03-312026-05-13open ↗
Frequently asked
- Is Zenas BioPharma, Inc. (ZBIO) a buy?
- ZBIO currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 100.0% YoY; but unprofitable (net margin -3777.4%).
- What is Zenas BioPharma, Inc.'s quality score?
- ZBIO scores 39.509803921568626/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001953926, latest 10-Q filed 2026-05-13) · EODHD · as of 6/26/2026, 6:08:48 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.